Drug Trial Radar · NCT06742216
Monosialoganglioside in Acute Ischemic Stroke: a Randomized, Blinded and Multicenter Confirmatory Study
Last checked: Nov 19, 2026Latest source record: Dec 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,232
Actual
Start
Nov 3, 2020
Primary completion
Aug 30, 2023
Study completion Aug 30, 2023
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multicenter, randomized, double-blind, parallel, placebo-controlled trial design is used to evaluate the efficacy and safety of GM1 injection in the treatment of patients with acute ischemic stroke. It is estimated that 1706 patients will be enrolled and randomly assigned to the treatment group and the placebo control group in a 1:1 ratio. Normally, the duration of this study is approximately 90 days. Treatment was continued for 12\~14 days, and follow-up was conducted until the 90th day from the first dose. The trial is divided into three phases: screening/baseline phase, treatment phase, and follow-up phase. Screening/baseline period: After the subjects sign the informed consent form, they enter the screening/baseline period for screening examination. Treatment period: Qualified subjects are randomly divided into groups in a 1:1 ratio and receive continuous treatment for 12\~14 days (12\~14 times) with GM1 injection and placebo respectively. During the treatment period, relevant examinations and evaluations required by the protocol will be carried out. Follow-up period: Subjects who have completed treatment will enter the follow-up period until the 90th day of treatment.
Conditions
- Acute Ischemic Stroke
Interventions
MonosialogangliosideDrug
Monosialoganglioside diluted with 0.9% normal saline 100ml, iv, daily for 12-14 days
PlaceboDrug
Placebo diluted with 0.9% normal saline 100ml, iv, daily for 12-14 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of modified Rankin Scale (mRS) 0-2Time frame: 90 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nanjing Gulou Medical College Affiliated Hospital
Nanjing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.